<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B42480C-C16B-45BD-A61E-FCB97FD77B2C"><gtr:id>8B42480C-C16B-45BD-A61E-FCB97FD77B2C</gtr:id><gtr:name>RIKEN</gtr:name><gtr:address><gtr:line1>1-7-22, Suehiro-cho</gtr:line1><gtr:line2>Tsurumi-ku</gtr:line2><gtr:line4>Yokohama</gtr:line4><gtr:line5>Kanagawa 230-0045</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Sir William Dunn Sch of Pathology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B42480C-C16B-45BD-A61E-FCB97FD77B2C"><gtr:id>8B42480C-C16B-45BD-A61E-FCB97FD77B2C</gtr:id><gtr:name>RIKEN</gtr:name><gtr:address><gtr:line1>1-7-22, Suehiro-cho</gtr:line1><gtr:line2>Tsurumi-ku</gtr:line2><gtr:line4>Yokohama</gtr:line4><gtr:line5>Kanagawa 230-0045</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/13FD1EF0-BFFC-4E6A-871F-AB23CEA96DCE"><gtr:id>13FD1EF0-BFFC-4E6A-871F-AB23CEA96DCE</gtr:id><gtr:firstName>Herman</gtr:firstName><gtr:surname>Waldmann</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/54A99119-BFC7-485F-82CB-E6CD0FCB4399"><gtr:id>54A99119-BFC7-485F-82CB-E6CD0FCB4399</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>P</gtr:otherNames><gtr:surname>Cobbold</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000215"><gtr:id>CF91DBF7-73DE-41CC-B4F0-6F2A3E438055</gtr:id><gtr:title>Therapeutic Immunoregulation.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000215</gtr:grantReference><gtr:abstractText>We will establish the rules by which the immune system can be encouraged to take control and reverse immune and inflammatory damage to body tissues. The main emphasis will be to characterise a special set of peacemaker lymphocytes (regulatory T cells) that have the capacity to curb inflammation. By understanding how these cells function we will be in a better position to exploit them, or even to bypass them, with new forms of targeted medication. This information should lead to improved strategies to harness natural regulatory mechanisms to control unwanted inflammatory and immune damage We have exhibited at Royal Society soirees and exhibitions, and have given lay lectures on ?reprogramming? and therapeutic antibodies to the Royal Institution and to school parties visiting Oxford. We maintain an active website http://users.path.ox.ac.uk/~scobbold/tig/welcome.html that lays out our research activities.</gtr:abstractText><gtr:technicalSummary>We discovered, in mice, that short courses of therapy with certain antibodies directed against T-cells could give long-term tolerance to foreign proteins and transplanted tissues, and could restore tolerance in autoimmunity. We have shown that short-term anti-T-cell therapy can also have long-term clinical benefits in multiple sclerosis and in Type I diabetes. The proper harnessing of this ?reprogramming? for clinical application requires that we should understand its mechanisms. Mouse models have taught us that, in most cases, tolerance requires the activity of CD4+ regulatory T-cells (Treg) that provide collateral protection to many antigens in the same tissue, and a role for the cytokine TGFbeta. Our capacity to understand how and when Treg operate has been constrained by the lack of a clear targetable cell surface marker. This we have now circumvented by creating a knock-in mouse with a human CD2/CD52 chimeric construct expressed under the control of the Foxp3 gene. In this way all Foxp3-expressing cells can now be identified or ablated with antibodies. Our derivation of a T-cell leukaemia line which can be easily induced to expresss Foxp3, provides a resource to investigate signalling pathways leading to the induction of Foxp3. In this program we hope to: 1) Use our ablative approaches to establish if and when Foxp3+ Treg act in the induction and maintenance of tolerance, linked suppression, and infectious tolerance; 2) Extend our recent discoveries that Treg and TGFbeta turn on cascades of enzymes concerned with catabolism of essential amino acids, and the generation of adenosine and, in conjunction with effects on the mTOR pathway, convert other T-cells to regulatory function. 3) Interrogate the role of the tissue microenvironment in promoting the function and further generation of Treg. 4) Utilise this information to develop improved strategies to harness regulatory mechanisms to control unwanted inflammatory and immune damage.</gtr:technicalSummary><gtr:fund><gtr:end>2014-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1121651</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Genzyme Corporation</gtr:department><gtr:description>role of TGfb in immunological tolerance</gtr:description><gtr:id>096A0C4B-6812-4585-B4E1-4ED0F8E299F2</gtr:id><gtr:impact>identified new roles for TGFb in evoking adenosine generation</gtr:impact><gtr:outcomeId>HQjLnZ2ydy7-1</gtr:outcomeId><gtr:partnerContribution>provision of reagents</gtr:partnerContribution><gtr:piContribution>readout assays</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>RIKEN</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>the construction of a novel reporter mouse for FoxP3 expression - Dr Shohei Hori</gtr:description><gtr:id>46882FB0-ABCC-4B27-A0DD-C5F80D658733</gtr:id><gtr:impact>The kendal paper in J. Exp.medicine this year (2011)</gtr:impact><gtr:outcomeId>J4qmB6WDNQB-1</gtr:outcomeId><gtr:partnerContribution>creation of a useful nmouse strain ck and ablate regulatoy T-cells</gtr:partnerContribution><gtr:piContribution>Creation of the reporter construct</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>a mouse expressing human CD2 on its regulatory T-cells, so permitting tracking, isolation and ablation of this cell type for research</gtr:description><gtr:id>8AD0888B-8606-4708-8566-D582A77515E0</gtr:id><gtr:impact>a new opportunity to study a cell type with huge therapeutic implications</gtr:impact><gtr:outcomeId>BJEvL9TGJ1D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>a transgenic mouse for tracking regulatory T-cells</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>42C249DD-1A5E-4C26-9512-73D79B2FAF8F</gtr:id><gtr:title>The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4T cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5c46e35c88b22df756168abc1900544"><gtr:id>b5c46e35c88b22df756168abc1900544</gtr:id><gtr:otherNames>Besan?on A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a9fbedf00ea89.91511725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EABB9A26-853A-4BCB-A8DB-817D92060CB1</gtr:id><gtr:title>mTOR signalling and metabolic regulation of T cell differentiation.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b052cf2628fd5b1d9aeae88e40d7519"><gtr:id>2b052cf2628fd5b1d9aeae88e40d7519</gtr:id><gtr:otherNames>Peter C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>E1BvNggWmVk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48DA003A-0364-43DA-9D81-E09E9672FD4A</gtr:id><gtr:title>Tolerogenicity is not an absolute property of a dendritic cell.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2eb04a0ddbd30b517dbc08a9fee2f213"><gtr:id>2eb04a0ddbd30b517dbc08a9fee2f213</gtr:id><gtr:otherNames>Farquhar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14770_20_20373289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B9111C9-579C-4207-BA63-255FF4DC0EA8</gtr:id><gtr:title>A novel role for Glucocorticoid-Induced TNF Receptor Ligand (Gitrl) in early embryonic zebrafish development.</gtr:title><gtr:parentPublicationTitle>The International journal of developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c41d2bf9a341063b77248da8e2ea40a"><gtr:id>7c41d2bf9a341063b77248da8e2ea40a</gtr:id><gtr:otherNames>Poulton LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0214-6282</gtr:issn><gtr:outcomeId>B343EC1FC34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2206CAF7-9055-4A24-ADF0-C7B725BB75F2</gtr:id><gtr:title>Secreted and transmembrane 1A is a novel co-stimulatory ligand.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ee12a2614ed8a1358b7add17f976e24"><gtr:id>0ee12a2614ed8a1358b7add17f976e24</gtr:id><gtr:otherNames>Howie D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14770_20_24039998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>483E9F71-B7CB-4866-9F6C-92C0B643D3C8</gtr:id><gtr:title>The plasticity and stability of regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b60670a5427ab39a8dbcf977957c19b6"><gtr:id>b60670a5427ab39a8dbcf977957c19b6</gtr:id><gtr:otherNames>Sakaguchi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>pm_14770_20_23681097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ADF0F6F-0487-4934-A259-9D3CA1855E93</gtr:id><gtr:title>Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a16dee3e0dff3afea458be6b9315d598"><gtr:id>a16dee3e0dff3afea458be6b9315d598</gtr:id><gtr:otherNames>Ponte JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>JgZiMVeD5Gy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7676F3-2E18-43ED-BA44-FDD1757AC449</gtr:id><gtr:title>Infectious tolerance: therapeutic potential.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b240ed766f8543399d16ce7cc3365bfd"><gtr:id>b240ed766f8543399d16ce7cc3365bfd</gtr:id><gtr:otherNames>Kendal AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>XCk1gsMydaq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9122EC6-3813-4EBA-AB47-58102763C8A4</gtr:id><gtr:title>Guiding postablative lymphocyte reconstitution as a route toward transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c18e4505cbd8730b0962664740b1d41"><gtr:id>1c18e4505cbd8730b0962664740b1d41</gtr:id><gtr:otherNames>Piotti G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>585d38e8886504.83446225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC813D33-9984-4562-AAB7-9131443034F4</gtr:id><gtr:title>Tolerance: an overview and perspectives.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-5061</gtr:issn><gtr:outcomeId>aHnjP8Pijhy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD5F4517-9672-4CEC-8716-03B41248A3E5</gtr:id><gtr:title>Foxp3 expression is required for the induction of therapeutic tissue tolerance.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/900e4a7bc9765800a9634035381a53ef"><gtr:id>900e4a7bc9765800a9634035381a53ef</gtr:id><gtr:otherNames>Regateiro FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14770_20_22988034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0414A941-CD74-4DFE-A93A-D58DDBDF1279</gtr:id><gtr:title>Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0c78b743c27d2022e1bd4fa3da26204"><gtr:id>b0c78b743c27d2022e1bd4fa3da26204</gtr:id><gtr:otherNames>Miyao T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>pm_14770_20_22326580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4422710-BA66-4CED-A785-A3228F33BC16</gtr:id><gtr:title>CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.</gtr:title><gtr:parentPublicationTitle>The review of diabetic studies : RDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cab5d476e92a29a28c6c4363b35f9f94"><gtr:id>cab5d476e92a29a28c6c4363b35f9f94</gtr:id><gtr:otherNames>Chatenoud L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1613-6071</gtr:issn><gtr:outcomeId>pm_14770_20_23804274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB88D408-65BB-40A5-A2EC-FD2B6595B885</gtr:id><gtr:title>Regulatory T cells and transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd8650137b3c0ff0e77db52f6d5c3d5"><gtr:id>bbd8650137b3c0ff0e77db52f6d5c3d5</gtr:id><gtr:otherNames>Hilbrands R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>pm_14770_20_23829623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A63BA56D-6169-4E89-92BF-99952F5F8F07</gtr:id><gtr:title>The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/841b7a58843e2f728fb7b8e13cfe78b7"><gtr:id>841b7a58843e2f728fb7b8e13cfe78b7</gtr:id><gtr:otherNames>Sekiya T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>ZQ3ckcyqkFh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46A3607A-B823-4A44-A221-ABDA3E691725</gtr:id><gtr:title>Regulation of the immune response.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e0b8e9b4a643e298cd47181d78555e7"><gtr:id>7e0b8e9b4a643e298cd47181d78555e7</gtr:id><gtr:otherNames>Greene MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>MVbdqfob3Qu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2B041A4-E276-45B5-A218-21BC2AE8EFC4</gtr:id><gtr:title>Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b240ed766f8543399d16ce7cc3365bfd"><gtr:id>b240ed766f8543399d16ce7cc3365bfd</gtr:id><gtr:otherNames>Kendal AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>JHaXQDzPmj7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD27F1BC-1780-417B-99DC-C549AE97DB51</gtr:id><gtr:title>TGF-? in transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/900e4a7bc9765800a9634035381a53ef"><gtr:id>900e4a7bc9765800a9634035381a53ef</gtr:id><gtr:otherNames>Regateiro FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>sUt6MTgQMdh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B22AE77-AA68-4063-B4DE-1F60F38E3F09</gtr:id><gtr:title>Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffceb12522ddfcc1b45e3dd4aa6349eb"><gtr:id>ffceb12522ddfcc1b45e3dd4aa6349eb</gtr:id><gtr:otherNames>Cobbold SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>pm_14770_20_20636819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7C065EC-CB99-4234-AC94-B794B7B53A74</gtr:id><gtr:title>Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-?.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/900e4a7bc9765800a9634035381a53ef"><gtr:id>900e4a7bc9765800a9634035381a53ef</gtr:id><gtr:otherNames>Regateiro FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>B4TtmsYQyQe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D33F730-F213-4C63-85D5-76E5CFF3A29A</gtr:id><gtr:title>Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fabf686eaf21842f5ea0ebe5c70d8530"><gtr:id>fabf686eaf21842f5ea0ebe5c70d8530</gtr:id><gtr:otherNames>McIntosh JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>S3hvAsCrdEx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F3FBDDF-52F2-4475-92CA-D81F4C82DC3D</gtr:id><gtr:title>Regulatory cells and transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffceb12522ddfcc1b45e3dd4aa6349eb"><gtr:id>ffceb12522ddfcc1b45e3dd4aa6349eb</gtr:id><gtr:otherNames>Cobbold SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_14770_20_23732858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E6B8FE-A45A-4572-899A-7476C1B64EE1</gtr:id><gtr:title>Biomarkers of transplantation tolerance: more hopeful than helpful?</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffceb12522ddfcc1b45e3dd4aa6349eb"><gtr:id>ffceb12522ddfcc1b45e3dd4aa6349eb</gtr:id><gtr:otherNames>Cobbold SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>pm_14770_20_22566800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55E5C521-A86A-45B8-9A69-054540049B54</gtr:id><gtr:title>Th17 cells induce a distinct graft rejection response that does not require IL-17A.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b05f0e49c63e5ef3e5a1e2e361df001f"><gtr:id>b05f0e49c63e5ef3e5a1e2e361df001f</gtr:id><gtr:otherNames>Agorogiannis EI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_14770_20_22390151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF179A25-BF01-4539-AB92-369F30303E24</gtr:id><gtr:title>Tmem176B and Tmem176A are associated with the immature state of dendritic cells.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b48207dec524ff84f8a57b7aee25007"><gtr:id>4b48207dec524ff84f8a57b7aee25007</gtr:id><gtr:otherNames>Condamine T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>J3JoibZdN2t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D887EBB3-4CF3-4FCC-AB59-489E2CBE6672</gtr:id><gtr:title>Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24b0d81994630ef5d940404cf94e605b"><gtr:id>24b0d81994630ef5d940404cf94e605b</gtr:id><gtr:otherNames>Mehta DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>ToEdeiRw8Nf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09F76197-32E0-49C4-B66D-A63AFC92F652</gtr:id><gtr:title>A role for regulatory T cells in acceptance of ESC-derived tissues transplanted across an major histocompatibility complex barrier.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/760d02a5d76154f04677d338e441b556"><gtr:id>760d02a5d76154f04677d338e441b556</gtr:id><gtr:otherNames>Lui KO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>XgB5MXbj2AA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C87A5A1-51DB-4938-809E-74B834C5B952</gtr:id><gtr:title>Human monoclonal antibodies: the residual challenge of antibody immunogenicity.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_14770_20_24037833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3301E310-6750-452C-B035-4B4877B5CAE9</gtr:id><gtr:title>Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c64eb0e771b1ce6789eb409d7e8cd52"><gtr:id>7c64eb0e771b1ce6789eb409d7e8cd52</gtr:id><gtr:otherNames>Keymeulen B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>BpvDsitWtTU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69F3F68E-4E6B-4C0B-8A97-B02E0A360F14</gtr:id><gtr:title>Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/089930c0c9b6aa2d9efe36a48b59efe1"><gtr:id>089930c0c9b6aa2d9efe36a48b59efe1</gtr:id><gtr:otherNames>Hale G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0091-2700</gtr:issn><gtr:outcomeId>BH9X4r2pHGW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EF5DF80-DF8A-4F63-8D0E-7215800D9BBF</gtr:id><gtr:title>Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa3b96da6331a7b88e45524e36294a96"><gtr:id>aa3b96da6331a7b88e45524e36294a96</gtr:id><gtr:otherNames>Tomura M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>BySutsNYkhU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>210C383C-B54B-4B35-9A84-E58A8463C530</gtr:id><gtr:title>A novel strategy to reduce the immunogenicity of biological therapies.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e0ef02971cf9a7838255a7e9c88685d"><gtr:id>5e0ef02971cf9a7838255a7e9c88685d</gtr:id><gtr:otherNames>Somerfield J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>r4LcA6W73vA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF883660-46FD-4A9A-95DD-6A2EF8335051</gtr:id><gtr:title>Activation rather than Foxp3 expression determines that TGF-?-induced regulatory T cells out-compete na&amp;iuml;ve T cells in dendritic cell clustering.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabb4a3c08d22654d635504cdccd286f"><gtr:id>aabb4a3c08d22654d635504cdccd286f</gtr:id><gtr:otherNames>Chen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14770_20_22678900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68BFD0A7-27C4-408F-A89F-C428CB29D5C9</gtr:id><gtr:title>Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy.</gtr:title><gtr:parentPublicationTitle>Current stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/760d02a5d76154f04677d338e441b556"><gtr:id>760d02a5d76154f04677d338e441b556</gtr:id><gtr:otherNames>Lui KO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1574-888X</gtr:issn><gtr:outcomeId>E134A6EE3AA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0440860-195A-4151-AAE4-5B24B5F11CCD</gtr:id><gtr:title>Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/961efde3d8aadd4bed68aaa22e6dcc5d"><gtr:id>961efde3d8aadd4bed68aaa22e6dcc5d</gtr:id><gtr:otherNames>Kuhn C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>i2jm2q74XK9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5856D4A6-E2A8-477B-8621-DA664598D00F</gtr:id><gtr:title>Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c64eb0e771b1ce6789eb409d7e8cd52"><gtr:id>7c64eb0e771b1ce6789eb409d7e8cd52</gtr:id><gtr:otherNames>Keymeulen B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>gnDhbuiie1q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A82E6A75-9C46-4B64-901B-64AFA241A31C</gtr:id><gtr:title>Enhanced murine contact hypersensitivity by depletion of endogenous regulatory T cells in the sensitization phase.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c39212187f2ac7453b537f87fbee699"><gtr:id>4c39212187f2ac7453b537f87fbee699</gtr:id><gtr:otherNames>Honda T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn><gtr:outcomeId>NAQa4uuJUAW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D854E726-0F01-494A-BC55-0D71FA23E64D</gtr:id><gtr:title>Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f61632074de67b069582d0c7a501a3d4"><gtr:id>f61632074de67b069582d0c7a501a3d4</gtr:id><gtr:otherNames>Tong H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>CfEabyURdYf</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000215</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>